DDInter1268 DDInter1628
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Bedaquiline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fludarabine
Fludarabine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fludarabine
Fludarabine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Clofarabine
Clofarabine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Clofarabine
Clofarabine {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) downregulates {v} (Gene) URB2
URB2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Clofarabine
Clofarabine {u} (Compound) upregulates {v} (Gene) SMNDC1
SMNDC1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) downregulates URB2 (Gene) and URB2 (Gene) is upregulated by Ruxolitinib (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine (Compound) upregulates SMNDC1 (Gene) and SMNDC1 (Gene) is upregulated by Ruxolitinib (Compound)